BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotech developing oral small molecule drugs targeting cancers driven by KRAS and PI3Kα mutations. BBOT has three drug candidates in Phase 1 trials. BBO-8520 is a KRAS G12C inhibitor that targets both the active and inactive states of the mutant protein, unlike the two approved KRAS G12C drugs (sotorasib and adagrasib), which only target the inactive state. BBOT argues that BBO-8520's dual-state mechanism and significantly lower drug exposure may enable better tolerability, particularly in combination with pembrolizumab, where approved KRAS inhibitors have run into liver toxicity issues. BBO-11818 is a pan-KRAS inhibitor targeting G12D, G12V, and G12C mutations — the G12D and G12V mutations have no approved targeted therapies, representing a large unaddressed patient population. BBO-10203 is a novel PI3Kα inhibitor that blocks RAS from activating PI3Kα, rather than inhibiting PI3Kα's kinase activity directly; because insulin signaling activates PI3Kα through a RAS-independent pathway, BBO-10203 avoids the hyperglycemia that limits existing PI3Kα drugs. BBOT's core strategy is to combine BBO-10203 with its KRAS inhibitors to simultaneously suppress both the MAPK and PI3Kα/AKT signaling pathways in tumor cells. BBOT has no approved products or revenue, and funds operations through capital raises. The company contracts out all manufacturing and plans to either commercialize approved drugs independently or partner with larger pharma companies.